WE BUILD COMPANIES
TO CHANGE THE WORLD


CATEGORIES

All Events
All News
Flywheel
Imbio
Invenshure
OneOme

HEADQUARTERS

  • T

  • 612.506.1234

  • 277 Colfax Avenue North
    Suite 148
    Minneapolis, MN 55405

Right the first time: How a Minneapolis company uses DNA tests to limit the side effects of psychiatric meds

Posted April 5, 2017

MinnPost published an article recounting the story of how OneOme’s RightMed pharmacogenomic test helped identify an effective prescription treatment for a teenager struggling with mental health conditions. For 10 years Carly and her family searched for the right medications and doses for her anxiety, ADHD, and depression. This process caused adverse drug reactions that had mentally and physically debilitating effects on Carly’s childhood. When she was 17 years old, her

Read More…

OneOme Receives Laboratory Clinical Certification from Five States

RIGHTMED TEST MITIGATES BARRIERS FOR IMPLEMENTING PHARMACOGENOMICS

Posted April 4, 2017

MINNEAPOLIS (March 27, 2017) – Pharmacogenomics company OneOme today announced the results of its clinician pharmacogenomic testing awareness survey. OneOme will formally share its findings at the Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, which begins March 27 in Denver. OneOme’s poster, Strategies for increasing clinician awareness of pharmacogenomic testing, will be presented on March 28, 2017 from 5:45-7:30 p.m. The study, conducted by

Read More…

OneOme Shares Findings of Pharmacogenomics Awareness Survey

RIGHTMED TEST MITIGATES BARRIERS FOR IMPLEMENTING PHARMACOGENOMICS

Posted April 3, 2017

MINNEAPOLIS (March 27, 2017) – Pharmacogenomics company OneOme today announced the results of its clinician pharmacogenomic testing awareness survey. OneOme will formally share its findings at the Academy of Managed Care Pharmacy (AMCP) Managed Care & Specialty Pharmacy Annual Meeting, which begins March 27 in Denver. OneOme’s poster, Strategies for increasing clinician awareness of pharmacogenomic testing, will be presented on March 28, 2017 from 5:45-7:30 p.m. The study, conducted by

Read More…

Results from OneOme’s RightMed test now can be integrated into a patient’s Electronic Medical Record (EMR)

Posted April 3, 2017

MINNEAPOLIS (March 21, 2017) – OneOme continues to make strides to ensure its powerful pharmacogenomics testing is a lasting tool for patients and healthcare providers. Results from OneOme’s RightMed test, which analyzes an individual’s DNA to predict his or her response to medications, now can be integrated into a patient’s Electronic Medical Record (EMR). Since a patient’s DNA does not change over time, the results can serve as a lifelong

Read More…

How Personalized Medicine Will Make Us Healthier

Posted April 3, 2017

Minnesota Monthly published an article describing how precision medicine can help improve people’s health, highlighting OneOme as a company that strives to bring precision medicine into routine clinical care. The article cites the example of a woman who suddenly fell so ill that she was hours from death. When taken to the hospital, the doctors realized the cause was the way in which her body was processing a medication that

Read More…

OneOme Announces New Specimen Option to Further Bring Its Powerful Pharmacogenomic Test into Routine Clinical Care

Posted April 3, 2017

MINNEAPOLIS (March 13, 2017) – OneOme today announced that healthcare providers now are able to order OneOme’s RightMed® pharmacogenomic test as part of an ordinary blood panel. Previously, the RightMed test was only available through a cheek swab. Making testing available using blood will further bring pharmacogenomic testing – the analysis of how a patient’s unique DNA affects their response to medications – into routine clinical care. By offering a

Read More…

Pharmacogenomics Company OneOme Announces Leadership Promotions

JASON ROSS WILL SERVE AS CHIEF TECHNOLOGY OFFICER, JOSIAH ALLEN PROMOTED TO DIRECTOR OF MEDICAL AFFAIRS

Posted April 3, 2017

MINNEAPOLIS (Jan. 26, 2017) – Pharmacogenomics company OneOme announced today that Jason Ross will serve as its chief technology officer and that Josiah Allen was promoted to OneOme’s director of medical affairs. “We are glad to add Josiah Allen and Jason Ross to our leadership team,” said Paul Owen, CEO of OneOme. “OneOme is on the cutting edge of making prescriptions personal, and Josiah and Jason bring the medical and

Read More…

Imbio Announces $1.5 Million Financing

FUND PRM LUNG, CT IMAGING BIOMARKER FOR COPD

Posted March 24, 2017

Imbio, LLC, a medical imaging software company, has closed on $1.5 million in Series A financing. Existing investor Invenshure, LLC, led the round with additional funding from several angel investors. The proceeds will support the commercialization of Imbio’s proprietary Parametric Response Mapping (PRM) technology used to detect, characterize and quantify abnormal tissue in computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET) images. “We appreciate the continued

Read More…

OneOme Selected to Participate at Upcoming Cavendish Global Health Impact Forum

Forum uniquely brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and the life sciences

Posted February 2, 2017

MINNEAPOLIS (Feb. 2, 2017) — OneOme, a pharmacogenomics company, announced today it has been selected to present at the ninth Cavendish Global Health Impact Forum taking place February 6-8, 2017 in San Diego, California. The Forum provides an environment for family offices, foundations and impact investors to develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences. To accomplish this mission, the

Read More…

During Heart Month, OneOme Highlights How RightMed® Pharmacogenomic Test Can Help People Taking Heart Medications

RIGHTMED PHARMACOGENOMIC TEST IS A NEW WAY FOR YOUR PHYSICIAN TO IMPROVE THE EFFECTIVENESS OF YOUR CARDIOVASCULAR PRESCRIPTIONS

Posted February 1, 2017

MINNEAPOLIS (Feb. 1, 2017) – This Heart Month, people suffering from heart conditions have a new opportunity to improve the effectiveness of their cardiovascular treatments through their healthcare provider: OneOme’s RightMed pharmacogenomic test. The RightMed test uses the power of DNA to minimize medication trial and error by determining which heart medications may work best for an individual patient. “Figuring out which heart medication will work best for you through

Read More…